(Q33751243)

29 July 2017

1 reference

title

Management of relapsed acute myeloid leukaemia (English)

1 reference

29 July 2017

1 reference

Webb DK

1

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 September 1999

1 reference

British Journal of Haematology

29 July 2017

published in

1 reference

29 July 2017

volume

106

1 reference

29 July 2017

issue

4

1 reference

29 July 2017

page(s)

851-859

1 reference

Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Par

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1999.01629.X

IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1999.01629.X

A randomised clinical trial comparing idarubicin and cytarabine to daunorubicin and cytarabine in the treatment of acute non-lymphoid leukaemia. A multicentric study from the Italian Co-operative Group GIMEMA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1999.01629.X

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1999.01629.X

Marked improvements in outcome with chemotherapy alone in paediatric acute myeloid leukemia: results of the United Kingdom Medical Research Council's 10th AML trial. MRC Childhood Leukaemia Working Party.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1999.01629.X

All-trans-retinoic acid in acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1999.01629.X

Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1999.01629.X

Outcome for children with relapsed acute myeloid leukaemia following initial therapy in the Medical Research Council (MRC) AML 10 trial. MRC Childhood Leukaemia Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1999.01629.X

FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1999.01629.X

Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1999.01629.X

Relapsing acute myeloid leukemia manifesting as hypopyon uveitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1999.01629.X

Second allogeneic bone marrow transplantation in acute leukemia: a multicenter study from the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO)

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1999.01629.X

The novel immunomodulator, Linomide, stimulates interleukin-2-induced human natural killer (NK) cell and PHA-stimulated T cell proliferation from normal donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1999.01629.X

Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1999.01629.X

Outcome of acute leukemia relapsing after bone marrow transplantation: utility of second transplants and adoptive immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1999.01629.X

Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1999.01629.X

Duration of second complete remission in patients with acute myeloid leukemia treated with chemotherapy: a retrospective single-center study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1999.01629.X

Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: A single-centre experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1999.01629.X

High-dose cytosine arabinoside and etoposide: an effective regimen without anthracyclines for refractory childhood acute non-lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.1999.01629.X

10.1046/J.1365-2141.1999.01629.X

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference